



OPEN

Study of risk factor of urinary calculi according to the association between stone composition with urine component

Pan Wang¹, Hongxian Zhang², Jiansuo Zhou¹, Shangjia Jin¹, Chong Liu¹, Boxin Yang¹ & Liyan Cui¹✉

Urolithiasis is a common urinary disease with high recurrence. The risk factor for the recurrence of calculi is not very clear. The object of the present study was to evaluate the association between calculi composition and urine component and analyse the risk factor for the recurrence of urolithiasis. In this study, a total of 223 patients with calculi and healthy control were enrolled, and the components of the calculi and urina sanguinis collected before surgery were analysed. Of the 223 patients, 157 were males and 66 were females. According to the stone composition, the case group was subdivided into three groups. 129 patients had single calcium oxalate stones, 72 had calcium oxalate stones mixed with other stones and 22 had other type of stones excluding calcium oxalate stones. Urine biochemicals were analysed and the associations were found between the chemicals in each group. Multivariate logistic analysis demonstrated that reduced urinary magnesium and uric oxalic acid were independent risk factors when comparing all cases with normal controls. Only decreased urinary magnesium was found to be a risk factor comparing the single calcium oxalate group with normal control group. Low level of urinary magnesium and uric oxalic acid were found to be risk factors comparing the mixed calcium oxalate group with normal control group. No risk factor was found comparing the other stone group with normal control group. In conclusion, there were clear relationships between stone components and urine chemicals. Urine chemicals might be risk factors to predicate the occurrence of urolithiasis.

Urolithiasis is a common urinary disease that is characterized by the presence of stones within the renal pelvis, ureter, bladder or urethra¹. Recent epidemiological data demonstrate that the prevalence and incidence rates of urolithiasis have increased considerably in nearly all countries^{2–4}. According to the National Health and Nutrition Examination Survey, the prevalence of urolithiasis in the United States was 8.8% in 2010 compared with 3.2% in 1980⁵. In Asia, a stone-forming belt has stretched across western Asia and South Asia, including South Korea and Japan, with prevalence rates ranging from 5 to 19.1%^{6,7}. In addition, the prevalence of kidney stones has also risen from 4 to 6.4% over the past 30 years in China owing to lifestyle and dietary changes⁸. Unfortunately, recurrence is common, with an estimated 5-year recurrence rate of up to 30–50%. Several studies demonstrated that the recurrence rate of urinary calculi in cured patients increased annually after the initial stone event^{9–11}. These suggest that calculi formation, as a lifelong disease, should not only be treated but also prevented¹².

Urinary stones usually consist of more than one substance¹³. Generally, the majority (80%) of urinary stones are composed of calcium oxalate mixed with calcium phosphate, followed by uric acid, struvite and cystine, accounting for approximately 9%, 10% and 1%, respectively¹⁴. Calcium oxalate stones mainly comprise two major constituents, calcium oxalate monohydrate and calcium oxalate dehydrate and frequently contain a mixture of the two substances. Excessive supersaturation of minerals in urine can lead to crystal formation, growth, aggregation and retention in the urinary tract. In addition, studies have demonstrated that the compositions of calculi have undergone substantial changes, and the incidences of calcium oxalate and calcium phosphate in calculi have increased¹⁵. However, the knowledge related to changes is still scarce.

Recent years great advances have been made in the treatment and surgical management of patients with urinary stones. Stones can be dispersed by shockwave lithotripsy to enable them to pass through the urethra or

¹Department of Laboratory Medicine, Peking University Third Hospital, Beijing 100191, China. ²Department of Urology, Peking University Third Hospital, Beijing 100191, China. ✉email: cliyan@163.com

removed with the application of a series of minimally invasive methods, such as ureteroscopic lithotripsy and percutaneous nephrolithotripsy (PCNL). Besides, important progresses have also been made in understanding the calculi pathogenesis. Epidemiological studies have shown that calculi in the urinary system are not caused by a single factor but by the interactions of multiple factors, such as sex, ethnicity, age, climate, occupation and obesity^{16–19}. Therefore, it is essential to identify potential risk factors for the formation of an initial calculus to provide a sound basis to prevent recurrence.

Urine contains multiple kinds of minerals and urine biomarkers to predicate and diagnose diseases at early stage has been widely accepted²⁰. The supersaturation of minerals and a decrease in crystal inhibitors may increase the likelihood of stone formation, so analysing the composition of urine to discover the risks for stone formation might be a practical and reliable method. With this information in mind, we recruited 223 patients with calculi and some healthy control, stones and urina sanguinis were collected, then the mineralogical compositions of calculi as well as urinary oxalic acid, urinary citric acid, urinary uric acid and urinary phosphorus, urinary magnesium, and urinary calcium in calculi patients and normal control group were examined. Finally, the correlations between stone compositions with urine component were analysed and risk factors for the occurrence of urolithiasis were discovered and those might provide deeper insight into the aetiology of urolithiasis and improve its diagnosis and treatment.

Materials and methods

Patient selection. In this study, inpatients who diagnosed with urolithiasis underwent PCNL or ureteroscopic lithotripsy in the department of urology of the Peking University Third Hospital from November 2017 to April 2019 were enrolled. The purpose of the experiment was to examine the components of calculi and the morning urine and analyse the association between them. A total of 257 patients with confirmed stone component analysis were enrolled according to the enrolment conditions. Stone specimens were excluded from the study when records of patient age, sex, or urine composition before surgery ($n=34$) were not available. In addition, 20 healthy persons who reported no nephropathy or renal and urogenital disorders were recruited. We identifies the Ethics Committee of Peking University Third Hospital approved the experiments, including any relevant details and confirms that all experiments were performed in accordance with relevant named guidelines and regulations. In addition, written informed consents were obtained from all the participants or their legal guardians.

Stone analysis. Calculi specimens were washed with distilled water and then placed in an 80 °C oven for drying. A small portion (1 mg) of the stone specimen was mixed with 200 mg of potassium bromide, placed into an agate mortar, ground to a powder, and then pressed onto a translucent sheet with a thickness of approximately 1 mm for analysis by a LIIR-20 calculus infrared spectrometry automatic analyser (manufactured by Lambda Scientific Corporation, China).

Urine components analysis. 5 ml of the first morning urines were collected from healthy control and the inpatients before surgery and stored at – 80 °C until experimental use. Then, the components of urinary oxalic acid, urinary citric acid, urinary uric acid and urinary phosphorus, urinary magnesium, and urinary calcium were determined by the improved immunoturbidimetric method with an A25 automatic specific protein analyser.

Statistical analysis. All statistical analyses were conducted using IBM SPSS, vision 23. Chi-squared tests were used to calculate the differences between groups. Person's correlation test was used to analyse the correlation between stone compositions with urine components after log-data transformation. For comparison with the control group, logistic multifactor analyses were performed. The significance level was defined as statistically significant at $P < 0.05$ and very significant at $P < 0.01$.

Results

Characteristics of the population. Of the 223 patients in the study, the mean (standard deviation) age was 52.9 years (14.43 years), ranging from 19 to 86 years. The results demonstrated a sex predominance, with males accounting for 70.40% of the population and a male-to-female ratio of 2.38:1, which coincides with the epidemiological results²¹. The other detailed information of the patients and the control group is shown in Table 1. The characteristics of the control group matched well with those of the patient group.

Stone components. Stones were classified according to their fundamental component. For example, in the single calcium oxalate group, there were 129 patients with only a calcium oxalate calculus. The mixed calcium oxalate group included 72 patients with stones containing calcium oxalate and carbonate apatite; calcium oxalate and anhydrous uric acid; calcium oxalate and magnesium ammonium phosphate; calcium oxalate and calcium hydrogen phosphate; calcium oxalate and L-cystine; or calcium oxalate, carbonate apatite and magnesium ammonium phosphate. The other stone group included 22 patients with a stone containing only anhydrous uric acid, only carbonate apatite, only L-cystine, only ammonium urate, or sodium urate and ammonium urate. There were no significant differences in the sex distributions among the three stone groups. The urine components of the patient groups and normal control group were examined, and the median and mean values of urinary oxalic acid, urinary citric acid, urinary uric acid, urinary phosphorus, urinary magnesium and urinary calcium for each group are shown in Table 2.

Stone group			Normal control group	
Item	Number	Percentage (%)	Number	Percentage (%)
Sex				
Male	157	70.40	13	65.00
Female	66	29.60	7	35.00
Age				
< 45	65	29.15	2	10.00
45–60	68	30.49	9	45.00
> 60	90	40.36	9	45.00
Stone location				
Upper urinary trace	198	88.79		
Lower urinary tract	20	8.97		
Both upper and lower urinary tract	5	2.24		
Group				
Single COX group	129	57.85		
Mixed COX group	72	32.29		
Other group	22	9.87		

Table 1. Population data. COX calcium oxalate.

Component	Single COX group	Mixed COX group	Other group	Normal control
UUA ($\mu\text{mol/l}$)				
Median	925.5	1005.05	801.05	1917.7
Mean	1113.279 \pm 872.480	1102.251 \pm 779.023	886.964 \pm 751.801	1917.89 \pm 163.18
UP (mmol/l)				
Median	5.5	4.465	8.3	14.815
Mean	9.545 \pm 11.453	7.918 \pm 9.002	8.949 \pm 7.412	15.037 \pm 1.347
UMg (mmol/l)				
Median	0.9	0.7	0.95	2.90
Mean	1.19 \pm 1.021	1.036 \pm 0.850	1.2 \pm 0.899	2.865 \pm 0.262
UCA (mmol/l)				
Median	1.1	1.2	0.9	2.50
Mean	1.605 \pm 1.486	1.549 \pm 1.365	1.214 \pm 1.112	3.055 \pm 0.529
UOXA (mg/l)				
Median	7.99	8.2	9.92	16.965
Mean	11.376 \pm 12.760	10.9022 \pm 9.908	14.909 \pm 17.432	17.028 \pm 1.382
UCIT (mmol/l)				
Median	1.3	1.515	2.08	6.39
Mean	3.297 \pm 6.126	3.6408 \pm 5.174	7.052 \pm 12.319	6.452 \pm 0.552

Table 2. The median and mean value of urinary components in each group. UUA urinary uric acid, UP urinary phosphorus, UMg urinary magnesium, UCA urinary calcium, UOXA uric oxalic acid, UCIT urinary citric acid.

Correlation analysis of stone components with urine chemicals. An analysis of calculi in patients with only calcium oxalate stone was conducted, and we found that urinary uric acid was positively correlated with urinary phosphorus, urinary magnesium, urinary calcium and urine citrate; urinary phosphorus was positively correlated with urinary magnesium, urinary calcium and uric acid; urinary magnesium was positively correlated with urinary calcium and urine citric acid; and urinary calcium was positively correlated with urinary citric acid (Fig. 1a). Next, the correlations were analysed in patients with mixed calcium oxalate stones. The results showed that urinary uric acid was positively correlated with urinary phosphorus and urinary magnesium; urinary phosphorus was positively correlated with urinary magnesium and urinary calcium; and urinary magnesium was positively correlated with urinary calcium and urine citric acid (Fig. 1b). Moreover, there was a positive correlation between only urinary phosphorus and urinary citrate in the analysis of calculi in patients with other stones (Fig. 1c).



Figure 1. Association between stone components and urine chemicals were conducted in the single calcium oxalate group (a), mixed calcium oxalate group (b) and other stone group (c), respectively. *P* values were shown in the chart. The figure was performed using Python software version 3.8 (<https://www.python.org/>).

Multivariate logistic analysis of the risk factors. In each group, the presence or absence of calculi (1 = yes, 0 = no) was considered the dependent variable, and urinary uric acid, urinary phosphorus, urinary magnesium, urinary calcium, urinary oxalic acid, and urinary citric acid were considered the independent variables for the multifactor logistic regression analysis. Decreased urinary magnesium and uric oxalic acid were independent risk factors in the multivariate logistic analysis of all cases and normal controls (Fig. 2a and Supplementary Table S1). Only reduced urinary magnesium was found to be a risk factor in the multivariate analysis of the single calcium oxalate group and normal control group (Fig. 2b and Supplementary Table S2). Decreased urinary magnesium and uric oxalic acid were shown as risk factors in the multivariate analysis in the mixed calcium oxalate group and normal control group (Fig. 2c and Supplementary Table S3). No risk factors were identified in the multivariate logistic analysis in the other stone group and normal control group (Fig. 2d and Supplementary Table S4).

Discussion

It is well known that the supersaturation of urinary salts or a reduction in crystal inhibitors leads to an increased risk of stone formation; therefore, urine component testing can predict the risk of urinary stone formation in a timely manner and appropriate precautions can be taken to reduce the possibility of stone formation. In recent years, several studies have confirmed that most patients with urolithiasis suffer from hyperuric calcium, hyperuricuria, low urinary magnesium or low citric aciduria^{22–26}. Twenty-four-hour urine biochemistry is generally considered the gold standard for the evaluation of urinary calculi metabolism, but some scholars have found that urine biochemical parameters of urina sanguinis are in good agreement with those of 24-h urine with respect to urine protein/urinary creatinine, urine phosphorus and uric acid, so urina sanguinis could be used as a substitute for 24-h urine for urinary calculi metabolism evaluation²⁷. Our study analysed the first morning urine composition of calculus patients and normal people to reveal the relationships between urinary calcium, magnesium, phosphorus, oxalic acid, uric acid, citric acid and stone composition. The limitation of our experiment was that we did not compare and rectify the urine chemical data to confirm the consistency between morning urine with 24-h urine.

Most patients with urinary stones in China have calcium-containing stones, of which calcium oxalate stones are the primary type. Studies demonstrated that 90% of calcium oxalate dihydrate stones were associated with hypercalciuria²⁸; however, other studies found that a high calcium diet was not related to the formation of hypercalciuria, and there was no correlation between dietary calcium and stone formation in adult men aged 60 years or older²⁹. In addition, Sorensen et al.³⁰ discovered that an increase in calcium in the diet can effectively reduce the incidence of kidney stones in female patients with urolithiasis. In this study, there was a positive linear correlation between urinary calcium and urinary uric acid, urinary magnesium, urinary phosphorus, and urinary citric acid in the single calcium oxalate stone group and with urinary phosphorus and urinary magnesium in the mixed calcium oxalate group.

The results of this study showed that the amount of urine oxalic acid in the total case group and mixed calcium oxalate group were also different from those in the normal control group in the multivariate analysis. After the multivariate logistic analysis, we found that every additional unit of urinary oxalic acid decreased the incidence of stones by 3.5% in the total case group and by 8% in the mixed calcium oxalate group. Several other reports^{31,32} manifest that hyperoxaluria is one of the independent risk factors for stone formation. In our experiment, we collected the morning urine from the inpatients who has been diagnosed with urolithiasis and ready for treatment, so the oxalic acid might have bound to calcium to form calcium oxalate. Therefore, the amount of the oxalic acid in cases group seems lower than control.

In recent years, the role of urinary magnesium in urolithiasis has been controversial³³. Many studies have shown that urinary magnesium can inhibit the formation of calcium oxalate crystals and stones³⁴, but some scholars discovered that the level of magnesium was higher in hypercalciuric stone formers than healthy subjects³⁵. In our study, by comparing the correlations of urine stone components in each stone group, we found that in the single calcium oxalate stone group and the mixed calcium oxalate stone group, urinary magnesium was associated with urinary uric acid, urinary calcium, urinary phosphorus and urinary citric acid. Besides, the results of this study showed that the amount of urine magnesium was significantly different between the normal control group and the single calcium oxalate group and the mixed calcium oxalate group. After the multivariate logistic




Figure 2. Risk factors were analysed through the multivariate logistic analysis between normal controls with all cases (a) or the single calcium oxalate group (b) or mixed calcium oxalate group (c) or other stone group (d), respectively. The figure was performed using Python software version 3.8 (<https://www.python.org/>).

analysis, we found that similar to urine oxalic acid, in the case group, a 1 unit decrease in urine magnesium increased the risk of stone formation by 1.1 times, while in the single calcium oxalate group, the risk increased by 1.2 times; the risk increased as high as 1.5 times in the mixed calcium oxalate stone group. Given that 90% percent of the enrolled patients have calcium oxalate, our results coincided with above results that hypercalciuric stone formers had lower urinary magnesium.

Studies have shown that urease-producing bacteria in urinary tract infections can decompose ammonia in the urine and alkalinize the urine, prolonged infection can promote the formation of calcium phosphate stones^{36,37}. In this study, urinary phosphorus was associated with urinary uric acid, urinary magnesium, urinary calcium, and urinary oxalic acid in the single calcium oxalate stone group; with urinary uric acid, urinary magnesium, urinary calcium in the mixed calcium oxalate stone group; and with urinary oxalic acid in the other stone group.

In a study by Wang Shu et al.¹⁷, it was found that the stone composition in most patients in China contained calcium oxalate monohydrate or calcium oxalate dihydrate, and the correlation between urinary oxalic acid and stone formation was not obvious, consistent with the results of this study. In this study, urinary oxalic acid was associated with urinary phosphorus in the single calcium oxalate stone group; with urinary citric acid in the mixed calcium oxalate stone group. Numerous studies have shown that urinary citric acid can effectively inhibit the formation of urinary stones, and low citric acid in urine is a symptom of urolithiasis in some patients³⁸.

However, in this study, urine citric acid was positively correlated with a variety of elements that promote the formation of urinary stones, which is inconsistent with other reported results, possibly due to the small sample size of healthy control group.

Conclusion

Through analysis of stone composition and urine ingredients of urolithiasis, we found some clear relationships between stone components and urinary chemicals. Furthermore, we also discovered that decreased urinary magnesium and urinary oxalic acid were independent risk factors for stones containing calcium oxalate, which were in agreement with previous results. Therefore, we presumed that the urinalysis could be used to predict the recurrence risk for urolithiasis who had calcium oxalate stones.

Received: 31 July 2020; Accepted: 30 March 2021

Published online: 22 April 2021

References

- Khan, S. R. *et al.* Kidney stones. *Nat. Rev. Dis. Primers* **2**, 16008. <https://doi.org/10.1038/nrdp.2016.8> (2016).
- Kittanamongkolchai, W. *et al.* The changing incidence and presentation of urinary stones over 3 decades. *Mayo Clin. Proc.* **93**, 291–299. <https://doi.org/10.1016/j.mayocp.2017.11.018> (2018).
- Liu, Y. *et al.* Epidemiology of urolithiasis in Asia. *Asian J. Urol.* **5**, 205–214. <https://doi.org/10.1016/j.ajur.2018.08.007> (2018).
- Karagiannis, A. *et al.* Epidemiologic study of urolithiasis in seven countries of South-Eastern Europe: S.E.G.U.R. 1 study. *Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica* **89**, 173–177. <https://doi.org/10.4081/aiua.2017.3.173> (2017).
- Scales, C. D. Jr., Smith, A. C., Hanley, J. M., Saigal, C. S. & Urologic Diseases in America, P. Prevalence of kidney stones in the United States. *Eur. Urol.* **62**, 160–165. <https://doi.org/10.1016/j.eururo.2012.03.052> (2012).
- Tae, B. S., Balpukov, U., Cho, S. Y. & Jeong, C. W. Eleven-year cumulative incidence and estimated lifetime prevalence of urolithiasis in Korea: A National Health Insurance Service-National Sample Cohort Based Study. *J. Korean Med. Sci.* **33**, e13. <https://doi.org/10.3346/jkms.2018.33.e13> (2018).
- Sakamoto, S. *et al.* Chronological changes in epidemiological characteristics of lower urinary tract urolithiasis in Japan. *Int. J. Urol.* **26**, 96–101. <https://doi.org/10.1111/iju.13817> (2019).
- Zeng, G. *et al.* Prevalence of kidney stones in China: An ultrasonography based cross-sectional study. *BJU Int.* **120**, 109–116. <https://doi.org/10.1111/bju.13828> (2017).
- Daudon, M., Jungers, P., Bazin, D. & Williams, J. C. Jr. Recurrence rates of urinary calculi according to stone composition and morphology. *Urolithiasis* **46**, 459–470. <https://doi.org/10.1007/s00240-018-1043-0> (2018).
- D'Costa, M. R. *et al.* Symptomatic and radiographic manifestations of kidney stone recurrence and their prediction by risk factors: A prospective cohort study. *J. Am. Soc. Nephrol.* **30**, 1251–1260. <https://doi.org/10.1681/ASN.2018121241> (2019).
- Ziemba, J. B. & Matlaga, B. R. Epidemiology and economics of nephrolithiasis. *Investig. Clin. Urol.* **58**, 299–306. <https://doi.org/10.4111/icu.2017.58.5.299> (2017).
- Fink, H. A. *et al.* Medical management to prevent recurrent nephrolithiasis in adults: A systematic review for an American College of Physicians Clinical Guideline. *Ann. Intern. Med.* **158**, 535–543. <https://doi.org/10.7326/0003-4819-158-7-201304020-00005> (2013).
- Mandel, N. S., Mandel, I. C. & Kolbach-Mandel, A. M. Accurate stone analysis: The impact on disease diagnosis and treatment. *Urolithiasis* **45**, 3–9. <https://doi.org/10.1007/s00240-016-0943-0> (2017).
- Evan, A. P. Physiopathology and etiology of stone formation in the kidney and the urinary tract. *Pediatr. Nephrol.* **25**, 831–841. <https://doi.org/10.1007/s00467-009-1116-y> (2010).
- Bae, S. R. *et al.* The epidemiology of reno-ureteral stone disease in Koreans: A nationwide population-based study. *Urolithiasis* **42**, 109–114. <https://doi.org/10.1007/s00240-014-0643-6> (2014).
- Taylor, E. N., Stampfer, M. J. & Curhan, G. C. Obesity, weight gain, and the risk of kidney stones. *JAMA* **293**, 455–462. <https://doi.org/10.1001/jama.293.4.455> (2005).
- Wang, S., Zhang, Y., Zhang, X., Tang, Y. & Li, J. Upper urinary tract stone compositions: The role of age and gender. *Int. Braz. J.* **46**, 70–80. <https://doi.org/10.1590/S1677-5538.IBJU.2019.0278> (2020).
- Shajari, A. & Sanjerehei, M. M. Modeling the distribution of urolithiasis prevalence under projected climate change in Iran. *Urolithiasis* **43**, 339–347. <https://doi.org/10.1007/s00240-015-0784-2> (2015).
- Goldfarb, D. S. The exposome for kidney stones. *Urolithiasis* **44**, 3–7. <https://doi.org/10.1007/s00240-015-0847-4> (2016).
- Jing, J. & Gao, Y. Urine biomarkers in the early stages of diseases: Current status and perspective. *Discov. Med.* **25**, 57–65 (2018).
- Roger, C. *et al.* Composition of urinary calculi: Lessons from a French epidemiologic retrospective study. *Progres en urologie: journal de l'Association francaise d'urologie et de la Societe francaise d'urologie* <https://doi.org/10.1016/j.purol.2020.03.003> (2020).
- Joshi, A., Gupta, S. K. & Srivastava, A. Metabolic evaluation in first-time renal stone formers in North India: A single center study. *Saudi J. Kidney Dis. Transplant.* **24**, 838–843. <https://doi.org/10.4103/1319-2442.113916> (2013).
- Gridley, C. M., Sourial, M. W., Lehman, A. & Knudsen, B. E. Medical dissolution therapy for the treatment of uric acid nephrolithiasis. *World J. Urol.* **37**, 2509–2515. <https://doi.org/10.1007/s00345-019-02688-9> (2019).
- Valente, P. *et al.* Metabolic syndrome and the composition of urinary calculi: Is there any relation?. *Central Eur. J. Urol.* **72**, 276–279. <https://doi.org/10.5173/cej.2019.1885> (2019).
- Rimer, J. D., Sakhaee, K. & Maalouf, N. M. Citrate therapy for calcium phosphate stones. *Curr. Opin. Nephrol. Hypertens.* **28**, 130–139. <https://doi.org/10.1097/MNH.0000000000000474> (2019).
- Atakan, I. H. *et al.* Serum, urinary and stone zinc, iron, magnesium and copper levels in idiopathic calcium oxalate stone patients. *Int. Urol. Nephrol.* **39**, 351–356. <https://doi.org/10.1007/s11255-006-9050-4> (2007).
- Whitton, C. *et al.* Evaluation of equations for predicting 24-hour urinary sodium excretion from casual urine samples in Asian adults. *J. Nutr.* **146**, 1609–1615. <https://doi.org/10.3945/jn.116.232108> (2016).
- Vale, L. *et al.* Metabolic evaluation in urolithiasis—study of the prevalence of metabolic abnormalities in a tertiary centre. *Central Eur. J. Urol.* **73**, 55–61. <https://doi.org/10.5173/cej.2020.0051> (2020).
- Taylor, E. N., Stampfer, M. J. & Curhan, G. C. Dietary factors and the risk of incident kidney stones in men: New insights after 14 years of follow-up. *J. Am. Soc. Nephrol.* **15**, 3225–3232. <https://doi.org/10.1097/01.ASN.0000146012.44570.20> (2004).
- Sorensen, M. D. *et al.* Impact of nutritional factors on incident kidney stone formation: A report from the WHI OS. *J. Urol.* **187**, 1645–1649. <https://doi.org/10.1016/j.juro.2011.12.077> (2012).
- Mitchell, T. *et al.* Dietary oxalate and kidney stone formation. *Am. J. Physiol. Ren. Physiol.* **316**, F409–F413. <https://doi.org/10.1152/ajprenal.00373.2018> (2019).

32. Holmes, R. P. & Assimos, D. G. The impact of dietary oxalate on kidney stone formation. *Urol. Res.* **32**, 311–316. <https://doi.org/10.1007/s00240-004-0437-3> (2004).
33. Ramaswamy, K. *et al.* The elementome of calcium-based urinary stones and its role in urolithiasis. *Nat. Rev. Urol.* **12**, 543–557. <https://doi.org/10.1038/nrurol.2015.208> (2015).
34. Han, H., Segal, A. M., Seifter, J. L. & Dwyer, J. T. Nutritional management of kidney stones (nephrolithiasis). *Clin. Nutr. Res.* **4**, 137–152. <https://doi.org/10.7762/cnr.2015.4.3.137> (2015).
35. Melo, T. L. *et al.* Expression of vitamin D receptor, CYP27B1 and CYP24A1 hydroxylases and 1,25-dihydroxyvitamin D3 levels in stone formers. *Urolithiasis* **48**, 19–26. <https://doi.org/10.1007/s00240-019-01163-9> (2020).
36. Bichler, K. H. *et al.* Urinary infection stones. *Int. J. Antimicrob. Agents* **19**, 488–498. [https://doi.org/10.1016/s0924-8579\(02\)00088-2](https://doi.org/10.1016/s0924-8579(02)00088-2) (2002).
37. Prywer, J. & Torzewska, A. Aggregation of poorly crystalline and amorphous components of infectious urinary stones is mediated by bacterial lipopolysaccharide. *Sci. Rep.* **9**, 17061. <https://doi.org/10.1038/s41598-019-53359-z> (2019).
38. del Valle, E. E., Spivacow, F. R. & Negri, A. L. Citrate and renal stones. *Medicina* **73**, 363–368 (2013).

Acknowledgements

This work was supported by National Natural Science Foundation of China Grant 61771022, 62071011 and 81971313, Key Clinical Projects of Peking University Third Hospital 2017017, National Key Research and Development Program 2017ZX09304012005 and Peking University Medicine Seed Fund for Interdisciplinary Research BMU2018MX005.

Author contributions

P.W., H.X.Z. and J.S.Z. contributed equally to this work. L.Y.C. conceived and supervised the experiment. P.W. wrote the manuscript and analysed the results. H.X.Z., J.S.Z. and S.J.J. conducted the experiment and analysed the results. C.L. and B.X.Y. collected the samples. All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary Information The online version contains supplementary material available at <https://doi.org/10.1038/s41598-021-87733-7>.

Correspondence and requests for materials should be addressed to L.C.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2021